Li, Xi
Montazeri, S. Ali
Paz-Fumagalli, Ricardo
Padula, Carlos A.
Wang, Weiping
Mody, Kabir
Roberts, Lewis R.
Patel, Tushar
Krishnan, Sunil
Toskich, Beau
Article History
Received: 24 September 2020
Accepted: 28 December 2020
First Online: 13 January 2021
Compliance with Ethical standards
:
: Dr. Krishnan reports grants from NIH, DoD, CPRIT, clinical research support from Celgene, Elekta outside the submitted work. In addition, Dr. Krishnan has patents pending or issued on radiation minibeams and gold nanoparticles. Dr. Mody reports and Research Support: Astrazeneca/Medimmune; Genentech; Senwha Biociences Inc; Basilea Pharma; Agios; Taiho Oncology; Merck KGa Serono; Puma Biotechnology. Consulting: AstraZeneca, Eisai, Bayer, Celgene, Ipsen. Grant Support: SPORE (NCI/NIH P50 CA210964). Dr. Patel reports grants from NIH, during the conduct of the study. Dr. Toskich is an advisor to Boston Scientific, Johnson and Johnson, Astra Zeneca, and Histosonics. Dr. Roberts reports grants from BTG International, grants from National Cancer Institute Grant P50 CA210964, grants from NIH NCATS Grant UL1 TR002377, during the conduct of the study; grants and other from Bayer, grants and other from Exact Sciences, grants and other from Gilead Sciences, grants from GlycoTest, other from GRAIL, Inc., other from QED Therapeutics, Inc., grants from RedHill Biopharma Ltd., grants from TARGET PharmaSolutions, other from TAVEC, grants from Wako Diagnostics, outside the submitted work. Dr. Li reports personal fees from China Scholarship Council, outside the submitted work. Drs. Padula, Wang, Montazeri, and Paz-Fumagalli have nothing to disclose.
: IRB approved the study. The need for consent was waived due to the retrospective design of the study.